News | March 23, 2008

B. Braun Recalls Heparin Lots After Supplier Finds Contamination

March 24, 2008 - B. Braun Medical Inc. was recently notified that 23 lots of its blood-thinning products containing heparin sodium USP active pharmaceutical ingredient are being recalled as part of the nationwide safety recall of heparin, prompted after the FDA found contamination in raw heparin stock imported from China.

The FDA has received reports of serious injuries and 19 deaths in patients who were administered heparin injectable products of other companies containing the contaminant. The FDA said last week the contaminant is oversulfated condroitin sulfate, which is used as a dietary supplement for joints, but can mimic heparin's blood-thinning properties in its oversulfated state. The FDA said as much as 50 percent of the recalled heparin was made up of the cheaper, substitute drug.

B. Braun began recalling the lots on March 21 as a precautionary measure. The company said the product recall was initiated after being notified by the supplier, Scientific Protein Laboratories (SPL), that one lot of heparin sodium, USP active pharmaceutical ingredient acquired by B. Braun had the contaminant. To date, B. Braun said it has not received any adverse event reports related to this issue.

As indicated in the notification issued by the SPL, typical symptoms include anaphylactic-like reactions such as low blood pressure, shortness of breath, nausea, vomiting, diarrhea and abdominal pain.

The voluntary recall affects the following 23 finished product lots manufactured and distributed by B. Braun Medical Inc. nationwide and to Canada. The recalled lots below are listed by B. Braun FP lot number first, followed by B. Braun FP material, description, U.S. NDC numbers, and ending with Candian DIN numbers:

- J7D490, P5872, Heparin Sodium 25,000 Units in 5 percent Dextrose Injection (250mL), 0264-9587-20
- J7C684, P5771, Heparin Sodium 25,000 Units in 5 percent Dextrose Injection (500mL), 0264-9577-10
- J7D496, P5771, Heparin Sodium 25,000 Units in 5 percent Dextrose Injection (500mL), 0264-9577-10
- J7C470, P5872, Heparin Sodium 25,000 Units in 5 percent Dextrose Injection (250mL), 0264-9587-20
- J7D580, P5671-00, Heparin Sodium 20,000 Units in 5 percent Dextrose Injection (500mL), Canadian DIN 02209713
- J7E420, P5872-00, Heparin Sodium 25,000 Units in 5 percent Dextrose Injection (250mL), Canadian DIN 02209721
- J7C611, P8721 Heparin Sodium 1000 Units in 0.9 percent Sodium Chloride Injection (500mL), 0264-9872-10, Candian DIN 01935933
- J7C557, P8721, Heparin Sodium 1000 Units in 0.9 percent Sodium Chloride Injection (500mL), 0264-9872-10, 01935933
- J7C477, P8721, Heparin Sodium 1000 Units in 0.9 percent Sodium Chloride Injection (500mL), 0264-9872-10, 01935933
- J7C705, P8721, Heparin Sodium 1000 Units in 0.9 percent Sodium Chloride Injection (500mL), 0264-9872-10, 01935933
- J7D485, P8721, Heparin Sodium 1000 Units in 0.9 percent Sodium Chloride Injection (500mL), 0264-9872-10, 01935933
- J7E415, P8721, Heparin Sodium 1000 Units in 0.9 percent Sodium Chloride Injection (500mL), 0264-9872-10, 01935933
- J7E416, P8721, Heparin Sodium 1000 Units in 0.9 percent Sodium Chloride Injection (500mL), 0264-9872-10, 01935933
- J7E494, P5872, Heparin Sodium 25,000 Units in 5 percent Dextrose Injection (250mL), 0264-9587-20
- J7E500, P5771, Heparin Sodium 25,000 Units in 5 percent Dextrose Injection (500mL), 0264-9577-10
- J7E577, P5771-00, Heparin Sodium 25,000 Units in 5 percent Dextrose Injection (500mL), Canadian DIN 01935941
- J7E489, P8721, Heparin Sodium 1000 Units in 0.9 percent Sodium Chloride Injection (500mL), 0264-9872-10, 01935933
- J7N556, P5872, Heparin Sodium 25,000 Units in 5 percent Dextrose Injection (250mL), 0264-9587-20
- J7P404, P5771, Heparin Sodium 25,000 Units in 5 percent Dextrose Injection (500mL), 0264-9577-10
- J7N604, P5771, Heparin Sodium 25,000 Units in 5 percent Dextrose Injection (500mL), 0264-9577-10
- J7P476, P5872, Heparin Sodium 25,000 Units in 5 percent Dextrose Injection (250mL), 0264-9587-20
- J7N519, P8721, Heparin Sodium 1000 Units in 0.9 percent Sodium Chloride Injection (500mL), 0264-9872-10, 01935933
- J7N676, P8721, Heparin Sodium 1000 Units in 0.9 percent Sodium Chloride Injection (500mL), 264-9872-10, 01935933

Adverse reactions or quality problems experienced in the U.S. with the use of these products can be reported to the FDA's MedWatch Adverse Event Reporting program either online at www.fda.gov/medwatch/report.htm, or by fax at 1-800-FDA-0178.

Adverse reactions or quality problems experienced in Canada with use of this product may be reported to Health Canada at www.hc-sc.gc.ca/dhp-mps/medeff/report-declaration/index_e.html

B. Braun said customers who have product in their possession from the recalled product lots should discontinue use immediately. Patients reporting any problems that may be related to the use of this product should be advised to contact a physician. Customers may contact B. Braun Medical Inc. customer support department at (800) 227-2862 for U.S. and (800) 624-2920 for Canada, Monday through Friday, 8 a.m. to 7 p.m. EST for instructions for handling the affected product and to arrange for replacement product.

For more information: www.fda.gov/medwAtch

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Study Discovers Anticoagulant Drugs Are Being Prescribed Against Safety Advice
News | Antiplatelet and Anticoagulation Therapies| July 25, 2017
July 25, 2017 — A study by researchers at the University of Birmingham has shown that general practitioners (GPs) are
long-duration dual anti-platelet therapy (L-DAPT) compared to short-duration dual antiplatelet (S-DAPT) after DES stent implantation
News | Antiplatelet and Anticoagulation Therapies| July 12, 2017
June 12, 2017 — Researchers have evaluated the long-term efficacy and safety of long-duration dual anti-platelet ther
Sex-Specific Cardiovascular Drug Dosages Needed to Reduce Adverse Reactions in Women
News | Womens Healthcare| July 07, 2017
Sex-specific cardiovascular drug dosages are needed to reduce adverse reactions in women, according to a position paper...
Bayer Now Enrolling Patients for Global Pulmonary Arterial Hypertension Study
News | Hypertension| July 05, 2017
Bayer has enrolled the first patient in a global Phase IV study assessing the clinical effects of riociguat in patients...
FDA Grants Priority Review of Xarelto sNDA for 10 mg Dose
News | Antiplatelet and Anticoagulation Therapies| June 29, 2017
Janssen Research & Development LLC announced the U.S. Food and Drug Administration (FDA) accepted for Priority...
radial access, transradial access trial using anticoagulants
News | Radial Access| June 15, 2017
June 15, 2017 — In patients undergoing t...
Cost comparison between NOACs, novel oral anticoagulants
News | Antiplatelet and Anticoagulation Therapies| May 31, 2017
May 31, 2017 – The results from the first real-world, matched head-to-head study comparing all-cause healthcare costs
Data was positive from the Watchman Left Atrial Appendage Closure (LAAC) Device from the EWOLUTION registry
News | Atrial Fibrillation| May 30, 2017
May 30, 2017 — Data was positive for safety and efficacy rates of the Watchman Left Atrial Appendage Closure (LAAC) D
Overlay Init